Colostrinin

also known as: PRP, Proline-Rich Polypeptide Complex, CLN

A colostrum-derived polypeptide complex — studied in clinical trials for Alzheimer's disease, with immunomodulatory activity that shifts cytokine profiles from pro- to anti-inflammatory.

A mixture of proline-rich polypeptides (PRPs, ~6 kDa) isolated from ovine colostrum, showing Th1/Th2 immunomodulatory activity and neuroprotective effects in early Alzheimer's disease clinical trials.

Mechanism of action

Modulates cytokine production, shifting the balance from pro-inflammatory Th1 toward anti-inflammatory Th2 responses. Inhibits beta-amyloid aggregation in vitro. Reduces oxidative stress via upregulation of antioxidant enzymes. The exact mechanism of cognitive benefit is not established.

Primary uses

Mild Alzheimer's disease (clinical trials)
Immune modulation research
Neuroprotection studies
Cognitive supplement

Typical dosing

100 mcg every other day for 3 weeks on, 3 weeks off cycles (oral (sublingual))

Dosing based on clinical trials. Available as tablet or sublingual formulation.

Regulatory status

Available as a dietary supplement (ReGen, various brands). Not FDA-approved as a drug. Small clinical trials in mild Alzheimer's showed modest cognitive stabilization.

References

[clinical-trial] Leszek J, et al. "Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease." Arch Immunol Ther Exp, 1999;47:377-385.
[review] Stewart MG. "Colostrinin: a naturally occurring compound derived from mammalian colostrum with efficacy in treatment of neurodegenerative diseases, including Alzheimer's." Expert Opin Pharmacother, 2008;9:2553-2559.

Related peptides

Cerebrolysin

A porcine-derived neurotrophic peptide preparation approved in 40+ countries (not US) for stroke, dementia, and traumatic brain injury — with the largest clinical evidence base of any nootropic peptide preparation.

Semax

A synthetic ACTH-derived heptapeptide approved in Russia for stroke rehabilitation and optic nerve disorders, with documented BDNF upregulation and broad nootropic activity.

Selank

A Russian-developed tuftsin analog approved for anxiety — produces benzodiazepine-like anxiolysis via GABAergic modulation without sedation, dependence, or withdrawal.

Davunetide

NAPVSIPQ, the minimum active fragment of ADNP — an 8-amino-acid neuroprotective peptide studied in Phase 2 (cognition in mild cognitive impairment, schizophrenia) and Phase 3 (progressive supranuclear palsy). The Phase 3 PSP trial failed in 2012; development continues in schizophrenia (Coronis / ATL-104) and ADNP syndrome research.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.